Skip to main content
Novonesis AS logo

Novonesis AS — Investor Relations & Filings

Ticker · NSIS ISIN · DK0060336014 LEI · 529900T6WNZXD2R3JW38 CO Manufacturing
Open in API
Filings indexed 2,308 across all filing types
Latest filing 2017-05-15 Director's Dealing
Country DK Denmark
Listing CO NSIS

About Novonesis AS

https://www.novozymes.com/en

Novonesis is a global biosolutions company formed through the combination of Novozymes and Chr. Hansen. The company develops and produces a broad portfolio of biological solutions, including industrial enzymes, functional proteins, and microorganisms such as cultures, probiotics, and yeast. Its products are utilized in over 30 industries to improve efficiency, sustainability, and product quality. Key markets include food and beverage, where solutions enhance nutrition and reduce waste; human and animal health; agriculture, promoting higher crop yields and animal welfare; and household care, for more effective cleaning. Novonesis applies biotechnological principles to address global challenges in production and consumption, aiming to create more sustainable systems and products.

Recent filings

Filing Released Lang Actions
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document explicitly references 'Regulation (EU) No 596/2014' (Market Abuse Regulation) and details 'transactions' under a specific ISIN and symbol. This structure strongly suggests a mandatory disclosure of insider transactions or transactions by persons discharging managerial responsibilities (PDMRs). The most fitting category among the provided definitions is 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives (insider trades). Although the text is very short and points to a PDF, the content is specific enough to classify it as DIRS rather than a general RPA or RNS.
2017-05-15 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 95% confidence The document is a detailed report of share transactions by a person closely associated with management, specifically Novo A/S related to the CEO and board member of Novozymes A/S. It references Regulation (EU) No 596/2014 on market abuse and provides extensive transaction details including volumes, prices, venues, and times. The content focuses on insider trading disclosures rather than financial results, management changes, or other corporate filings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is substantial and contains detailed transaction data, not just an announcement or summary, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is DIRS with high confidence.
2017-05-15 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Director's Dealing Classification · 100% confidence The document is a formal notification regarding transactions in the company's own shares by a person with managerial responsibilities (Novo A/S, related to a board member). It explicitly cites EU Market Abuse Regulation (MAR) Article 19 and provides detailed tables of share transactions, including volume, price, and venue. This fits the definition of a 'Director's Dealing' (DIRS) report, which covers insider trades and transactions by persons closely associated with directors.
2017-05-15 English
Regulatory Filings 2017
Regulatory Filings
2017-05-11 Danish
Director's Dealing 2017
Director's Dealing Classification · 100% confidence The document text explicitly details 'Trading by management and of close relations to management' and reports transactions (Sale of shares) by 'Novo A/S', which is closely associated with a CEO and board member of Novozymes A/S. This type of mandatory disclosure regarding personal share transactions by directors and executives falls directly under the definition of Director's Dealing (DIRS) as per EU Market Abuse Regulation (MAR) requirements mentioned in the text. It is not an earnings release, annual report, or general regulatory filing, but a specific insider transaction report.
2017-05-11 English
Transaktioner af ledende medarbejdere samt disses nærtstående
Report Publication Announcement Classification · 90% confidence The text is extremely short (under 5000 characters) and simply states that, in accordance with MAR article 19, Novozymes “reports the following transactions” under an ISIN and directs the reader to “Read the full announcement in PDF.” It does not contain any actual transaction details itself but instead points to a separate PDF. Per the “menu vs meal” rule, documents that merely announce the publication of a report and direct readers to an attachment should be classified as Report Publication Announcements (RPA), not as Director’s Dealing filings.
2017-05-11 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.